Peter Alfred LeWitt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter Alfred LeWitt has a total of 286 co-authors. Here are the top co-authors by number of shared publications:
Jia Li
Department of Public Health Science, Henry Ford Hospital, Detroit, USA
4 shared publicationsMei Lu
The Department of Public Health Science, Henry Ford Health System, Detroit, MI, USA
4 shared publications- Wei-Ling Tsou
Department of Pharmacology, Wayne State University School of Medicine, Detroit, USA
4 shared publications Zoya R. Bangash
Department of Pharmacology, Wayne State University School of Medicine, Detroit, USA
4 shared publicationsAlexander Sedkov
Acorda Therapeutics, Ardsley, NY, USA
3 shared publicationsMika Leinonen
Pharma AB, Stockholm, Sweden
3 shared publications
Latest Publications
- 12 October 2026
- Published by Wiley in European Journal of Neuroscience
- Vol. 64 (7) , e70711
Freezing of Gait: A Therapeutic Perspective
Despite improved definition of the problem and better understanding of its phenomenology, freezing of gait (FoG) remains a therapeutic enigma for clinicians and neuroscientists alike. Patients with Parkinson disease (PD) or other neurological disorders experiencing FoG are similarly frustrated, despite the benefits that levodopa and other medications provide for control of PD's primary motor features. For those burdened by episodes of FoG, current therapeutic options are quite limited. Some patients achieve improvements from pharmacotherapy—for example, by adjunctive use of an oral dopaminergic agonist or by subcutaneous infusion of apomorphine. If needed, deep brain stimulation sometimes offers symptomatic improvements. Certain interventions devised by physical therapists (or discovered by patients themselves) can improve FoG. However, successful pharmacotherapy for FoG has lagged behind, though the future holds some promising leads for therapies acting on dopaminergic, adenosinergic, noradrenergic, glutamatergic, and cholinergic circuitry.
- 12 October 2026
- Published by Wiley in European Journal of Neuroscience
- Vol. 64 (7) , e70711
Freezing of Gait: A Therapeutic Perspective
Despite improved definition of the problem and better understanding of its phenomenology, freezing of gait (FoG) remains a therapeutic enigma for clinicians and neuroscientists alike. Patients with Parkinson disease (PD) or other neurological disorders experiencing FoG are similarly frustrated, despite the benefits that levodopa and other medications provide for control of PD's primary motor features. For those burdened by episodes of FoG, current therapeutic options are quite limited. Some patients achieve improvements from pharmacotherapy—for example, by adjunctive use of an oral dopaminergic agonist or by subcutaneous infusion of apomorphine. If needed, deep brain stimulation sometimes offers symptomatic improvements. Certain interventions devised by physical therapists (or discovered by patients themselves) can improve FoG. However, successful pharmacotherapy for FoG has lagged behind, though the future holds some promising leads for therapies acting on dopaminergic, adenosinergic, noradrenergic, glutamatergic, and cholinergic circuitry.
- Open Access
- 30 August 2026
- Published by Springer Nature in Amino Acids
- Vol. 58 (1) , 48
Polyamine metabolic enzyme SAT1 remodels the neuronal transcriptome and rescues α-synuclein toxicity in Drosophila
Polyamine homeostasis is tightly regulated by interconversion and catabolic pathways and has been increasingly implicated in neurodegenerative disorders, including Parkinson’s disease (PD), where accumulation of α-synuclein (α-Syn) perturbs neuronal homeostasis. Spermidine/spermine N¹-acetyltransferase 1 (SAT1) occupies a central position in polyamine interconversion, and alterations in SAT1 activity have been linked to α-Syn toxicity and PD-related neuropathology. To investigate how SAT1 activity influences α-Syn-associated neurodegeneration, we employed a Drosophila model of neuronal α-Syn expression. SAT1 overexpression reduced α-Syn protein levels, altered its subcellular distribution within the brain, and mitigated α-Syn-induced lifespan shortening. Transcriptomic analyses showed that SAT1 modulates stress-associated gene expression in the α-Syn background, including attenuation of chaperone and ubiquitin-related responses and coordinated changes in pathways linked to mitochondrial function and amino acid metabolism. SAT1 co-expression partially restored α-Syn-associated alterations in genes involved in mitochondrial quality control, including USP30, Uch-L5R, RNF185, and the mitochondrial ornithine carrier SLC25A15. At the protein level, SAT1 increased mitochondrial-associated signal, enhanced LC3 association with mitochondrial compartments, restored LC3-II/LC3-I ratios in mitochondrial fractions, and reduced mitochondrial accumulation of α-Syn. Functional analyses further showed that SAT1 increased steady-state ATP levels and attenuated the ATP depletion induced by α-Syn expression. These findings indicate that SAT1 activity is associated with reduced α-Syn toxicity and preservation of mitochondrial homeostasis during α-Syn-associated stress.
- 30 August 2026
- Published by Springer Nature in Amino Acids
- Vol. 58 (1) , 48
Open AccessPolyamine metabolic enzyme SAT1 remodels the neuronal transcriptome and rescues α-synuclein toxicity in Drosophila
Polyamine homeostasis is tightly regulated by interconversion and catabolic pathways and has been increasingly implicated in neurodegenerative disorders, including Parkinson’s disease (PD), where accumulation of α-synuclein (α-Syn) perturbs neuronal homeostasis. Spermidine/spermine N¹-acetyltransferase 1 (SAT1) occupies a central position in polyamine interconversion, and alterations in SAT1 activity have been linked to α-Syn toxicity and PD-related neuropathology. To investigate how SAT1 activity influences α-Syn-associated neurodegeneration, we employed a Drosophila model of neuronal α-Syn expression. SAT1 overexpression reduced α-Syn protein levels, altered its subcellular distribution within the brain, and mitigated α-Syn-induced lifespan shortening. Transcriptomic analyses showed that SAT1 modulates stress-associated gene expression in the α-Syn background, including attenuation of chaperone and ubiquitin-related responses and coordinated changes in pathways linked to mitochondrial function and amino acid metabolism. SAT1 co-expression partially restored α-Syn-associated alterations in genes involved in mitochondrial quality control, including USP30, Uch-L5R, RNF185, and the mitochondrial ornithine carrier SLC25A15. At the protein level, SAT1 increased mitochondrial-associated signal, enhanced LC3 association with mitochondrial compartments, restored LC3-II/LC3-I ratios in mitochondrial fractions, and reduced mitochondrial accumulation of α-Syn. Functional analyses further showed that SAT1 increased steady-state ATP levels and attenuated the ATP depletion induced by α-Syn expression. These findings indicate that SAT1 activity is associated with reduced α-Syn toxicity and preservation of mitochondrial homeostasis during α-Syn-associated stress.
- Open Access
- 26 August 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (7) , 1615-1617
Impaired olfaction and Parkinsonism: A “hidden gem” in the neurological literature
Though impaired olfaction in Parkinson disease is now a widely accepted characteristic of this disorder, this discovery arose from several international case reports preceding the first formal research on this topic (conducted in 1975 by Ansari and Johnson). The clinical observations have supplemented findings by Braak and colleagues demonstrating that, like impaired sense of smell, olfactory bulb involvement by Lewy pathology is a common early feature in Parkinson disease.
- 26 August 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (7) , 1615-1617
Open AccessImpaired olfaction and Parkinsonism: A “hidden gem” in the neurological literature
Though impaired olfaction in Parkinson disease is now a widely accepted characteristic of this disorder, this discovery arose from several international case reports preceding the first formal research on this topic (conducted in 1975 by Ansari and Johnson). The clinical observations have supplemented findings by Braak and colleagues demonstrating that, like impaired sense of smell, olfactory bulb involvement by Lewy pathology is a common early feature in Parkinson disease.
- Open Access
- 13 August 2026
- Published by Elsevier in NeuroImage
- Vol. 339
Imaging biomarkers in Parkinson’s disease and movement disorders: emerging insights from multimodal neuroimaging
- 13 August 2026
- Published by Elsevier in NeuroImage
- Vol. 339
Open AccessImaging biomarkers in Parkinson’s disease and movement disorders: emerging insights from multimodal neuroimaging
- Open Access
- 24 July 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (6) , 1336-1339
Parkinsonism induced by carbon monoxide intoxication: A “hidden gem” in the neurological literature
Parkinsonism can be acquired by various toxic exposures, among them carbon monoxide. Since the publication of a 1972 report of Parkinsonism associated with repeated episodes of carbon monoxide exposure, the medical literature has recorded multiple cases. A distinctive bilateral change in a specific brain region, the globi pallidi, provides strong evidence for carbon monoxide-induced Parkinsonism. In addition to acute intoxication with carbon monoxide, more chronic environmental exposures may also increase the risk for Parkinsonism. Paradoxically, recent research suggests that exposure to low-dose carbon monoxide might actually have a protective effect against Parkinson disease - but this needs to be carefully and safely tested. Plain language summary title: Parkinsonism associated with carbon monoxide exposure
- 24 July 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (6) , 1336-1339
Open AccessParkinsonism induced by carbon monoxide intoxication: A “hidden gem” in the neurological literature
Parkinsonism can be acquired by various toxic exposures, among them carbon monoxide. Since the publication of a 1972 report of Parkinsonism associated with repeated episodes of carbon monoxide exposure, the medical literature has recorded multiple cases. A distinctive bilateral change in a specific brain region, the globi pallidi, provides strong evidence for carbon monoxide-induced Parkinsonism. In addition to acute intoxication with carbon monoxide, more chronic environmental exposures may also increase the risk for Parkinsonism. Paradoxically, recent research suggests that exposure to low-dose carbon monoxide might actually have a protective effect against Parkinson disease - but this needs to be carefully and safely tested. Plain language summary title: Parkinsonism associated with carbon monoxide exposure
- Open Access
- 7 May 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 148, 108342
A double-blind, randomized, multicenter, phase 2b study of the safety and efficacy of suvecaltamide in essential tremor
- 7 May 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 148, 108342
Open AccessA double-blind, randomized, multicenter, phase 2b study of the safety and efficacy of suvecaltamide in essential tremor
- Open Access
- 29 April 2026
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 49 (3) , 136-142
Opicapone Improves the Pharmacokinetics of Levodopa Administered as Extended-Release Capsules
Objective: Both a catechol-O-methyltransferase inhibitor and extended-release (ER) levodopa formulations may enhance levodopa treatment through a more continuous levodopa delivery to the striatum; the combination of these therapies has not undergone a pharmacokinetic study. We evaluated the effects of once-daily opicapone 50 mg on levodopa plasma pharmacokinetics when added to a carbidopa/levodopa (CD/LD)-ER formulation (RYTARY ® ). Materials and Methods: This was an exploratory, open-label study of levodopa’s pharmacokinetics measured over 24 hours in healthy adults. Enrolled individuals received CD/LD-ER three times daily (TID) alone for 3 days, followed by once-daily opicapone for 14 days. On the last 3 days of the opicapone regimen, participants received CD/LD ER TID again. Pharmacokinetic parameters were evaluated after the 3-day exposure to CD/LD-ER alone and with concomitant administration of opicapone. Results: Eighteen healthy adults (9 male, 9 female) entered and completed the study. Levodopa exposure (area under the time-concentration curve) was higher with opicapone than with CD/LD-ER alone across all dosing intervals, including between 21:00 and 07:00 (10801.5 vs. 5153.3 ng/mL·h). Over 24 hours, mean levodopa trough concentration (C trough ) was higher with opicapone versus CD/LD-ER alone (677.2 vs. 266.8 ng/mL), as was minimum C trough (302.9 vs. 41.3 ng/mL). There was a greater increase in C trough (208%) than in maximum plasma concentration (75%), decreasing the fluctuation index by 38%. Conclusions: Adding opicapone to CD/LD-ER enhanced levodopa pharmacokinetics in healthy adults, by increasing levodopa trough levels. Notably, opicapone increased overnight and morning levodopa concentrations and decreased daily levodopa concentrations, sub-therapeutic for Parkinson disease patients.
- 29 April 2026
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 49 (3) , 136-142
Open AccessOpicapone Improves the Pharmacokinetics of Levodopa Administered as Extended-Release Capsules
Objective: Both a catechol-O-methyltransferase inhibitor and extended-release (ER) levodopa formulations may enhance levodopa treatment through a more continuous levodopa delivery to the striatum; the combination of these therapies has not undergone a pharmacokinetic study. We evaluated the effects of once-daily opicapone 50 mg on levodopa plasma pharmacokinetics when added to a carbidopa/levodopa (CD/LD)-ER formulation (RYTARY ® ). Materials and Methods: This was an exploratory, open-label study of levodopa’s pharmacokinetics measured over 24 hours in healthy adults. Enrolled individuals received CD/LD-ER three times daily (TID) alone for 3 days, followed by once-daily opicapone for 14 days. On the last 3 days of the opicapone regimen, participants received CD/LD ER TID again. Pharmacokinetic parameters were evaluated after the 3-day exposure to CD/LD-ER alone and with concomitant administration of opicapone. Results: Eighteen healthy adults (9 male, 9 female) entered and completed the study. Levodopa exposure (area under the time-concentration curve) was higher with opicapone than with CD/LD-ER alone across all dosing intervals, including between 21:00 and 07:00 (10801.5 vs. 5153.3 ng/mL·h). Over 24 hours, mean levodopa trough concentration (C trough ) was higher with opicapone versus CD/LD-ER alone (677.2 vs. 266.8 ng/mL), as was minimum C trough (302.9 vs. 41.3 ng/mL). There was a greater increase in C trough (208%) than in maximum plasma concentration (75%), decreasing the fluctuation index by 38%. Conclusions: Adding opicapone to CD/LD-ER enhanced levodopa pharmacokinetics in healthy adults, by increasing levodopa trough levels. Notably, opicapone increased overnight and morning levodopa concentrations and decreased daily levodopa concentrations, sub-therapeutic for Parkinson disease patients.
- Open Access
- 7 April 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (3) , 609-611
Oxybutynin treatment for episodic hyperhidrosis in Parkinson disease
Not all medications arrive from a disciplined path of translational drug development; sometimes, the route of discovery involves serendipity. A drug developed for controlling urinary urgency, oxybutynin, is reviewed here as a highly effective treatment for excessive sweating (hyperhidrosis). Its use in Parkinson disease is described in a case report.
- 7 April 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (3) , 609-611
Open AccessOxybutynin treatment for episodic hyperhidrosis in Parkinson disease
Not all medications arrive from a disciplined path of translational drug development; sometimes, the route of discovery involves serendipity. A drug developed for controlling urinary urgency, oxybutynin, is reviewed here as a highly effective treatment for excessive sweating (hyperhidrosis). Its use in Parkinson disease is described in a case report.
- Top Cited Papers
- 10 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (3) , e214648
CSF α-Synuclein Seed Amplification Assays and Skin Immunofluorescence
The development of biomarkers capable of reliably detecting pathologic forms of α-synuclein (aSyn) in vivo marks a significant step forward in the field of neurodegeneration. Over the recent years, CSF aSyn seed amplification assays (aSyn-SAA) and skin biopsy phospho-aSyn immunofluorescence (skin aSyn-IF) testing were developed that detect pathologic aSyn seeds and phosphorylated aSyn aggregates, respectively, in patients with synucleinopathies, which include Parkinson disease, dementia with Lewy bodies, and also multiple system atrophy. High rates of positivity have also been documented in research participants at a risk of developing future aSyn-related disease (e.g., hyposmia and REM sleep behavior disorder), as well as other contexts. These assays have numerous potential applications in research settings and clinical care. Here, we review the currently published evidence supporting CSF aSyn-SAA and skin aSyn-IF testing and discuss their potential research applications in clinical trials. As CSF aSyn-SAA and skin aSyn-IF testing is now commercially available to clinicians in nonresearch settings, we also explore their current utility and limitations as diagnostic tools and call for the development of a formal clinical use guidelines. We also highlight where critical knowledge gaps remain and explore emerging developments related to these assays.
- 10 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (3) , e214648
Top Cited PapersCSF α-Synuclein Seed Amplification Assays and Skin Immunofluorescence
The development of biomarkers capable of reliably detecting pathologic forms of α-synuclein (aSyn) in vivo marks a significant step forward in the field of neurodegeneration. Over the recent years, CSF aSyn seed amplification assays (aSyn-SAA) and skin biopsy phospho-aSyn immunofluorescence (skin aSyn-IF) testing were developed that detect pathologic aSyn seeds and phosphorylated aSyn aggregates, respectively, in patients with synucleinopathies, which include Parkinson disease, dementia with Lewy bodies, and also multiple system atrophy. High rates of positivity have also been documented in research participants at a risk of developing future aSyn-related disease (e.g., hyposmia and REM sleep behavior disorder), as well as other contexts. These assays have numerous potential applications in research settings and clinical care. Here, we review the currently published evidence supporting CSF aSyn-SAA and skin aSyn-IF testing and discuss their potential research applications in clinical trials. As CSF aSyn-SAA and skin aSyn-IF testing is now commercially available to clinicians in nonresearch settings, we also explore their current utility and limitations as diagnostic tools and call for the development of a formal clinical use guidelines. We also highlight where critical knowledge gaps remain and explore emerging developments related to these assays.
- 12 January 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (4) , 1137-1143
The persisting puzzle of OFF time in advanced Parkinson’s disease
Despite multiple available strategies for managing motor fluctuations in advanced Parkinson’s disease, there is a continuing need for improved therapeutics. After 2–5 years of levodopa treatment, some patients start to experience OFF time that can last five or more hours per day. Responding to this challenge are pump-delivered infusion therapies for delivering carbidopa-levodopa or apomorphine. However, despite their ability to offer continuous dopaminergic stimulation, these options generally do not provide fluctuators with full control of daily OFF time. The complexity of managing motor fluctuations is further highlighted by the effectiveness of various non-dopaminergic adjunctive therapies for reducing OFF time in levodopa-treated patients, as shown by placebo-controlled clinical trials with adjunctive istradefylline, amantadine, zonisamide and deep brain stimulation. Other recent paradigm shifts for understanding levodopa’s role in Parkinson’s disease therapeutics are observations that reserpine-induced parkinsonism in mice can be reversed without its conversion to dopamine (and through levodopa-induced stimulation of ophthalmate release). To achieve better control of OFF time in advanced Parkinson’s disease, there is a need for therapeutic strategies that act beyond the limits of today’s dopaminergic therapies. Modelling brain circuitry with tools such as deterministic neural-computational analysis may provide valuable pharmacological and electrophysiological insights to better understand motor fluctuations and to inform the selection of appropriate therapeutic targets.
- 12 January 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (4) , 1137-1143
The persisting puzzle of OFF time in advanced Parkinson’s disease
Despite multiple available strategies for managing motor fluctuations in advanced Parkinson’s disease, there is a continuing need for improved therapeutics. After 2–5 years of levodopa treatment, some patients start to experience OFF time that can last five or more hours per day. Responding to this challenge are pump-delivered infusion therapies for delivering carbidopa-levodopa or apomorphine. However, despite their ability to offer continuous dopaminergic stimulation, these options generally do not provide fluctuators with full control of daily OFF time. The complexity of managing motor fluctuations is further highlighted by the effectiveness of various non-dopaminergic adjunctive therapies for reducing OFF time in levodopa-treated patients, as shown by placebo-controlled clinical trials with adjunctive istradefylline, amantadine, zonisamide and deep brain stimulation. Other recent paradigm shifts for understanding levodopa’s role in Parkinson’s disease therapeutics are observations that reserpine-induced parkinsonism in mice can be reversed without its conversion to dopamine (and through levodopa-induced stimulation of ophthalmate release). To achieve better control of OFF time in advanced Parkinson’s disease, there is a need for therapeutic strategies that act beyond the limits of today’s dopaminergic therapies. Modelling brain circuitry with tools such as deterministic neural-computational analysis may provide valuable pharmacological and electrophysiological insights to better understand motor fluctuations and to inform the selection of appropriate therapeutic targets.